Literature DB >> 23522890

Rituximab for the treatment of high titre inhibitors in mild haemophilia A.

Majda Benedik Dolničar1, Vladan Rajić1, Lidija Kitanovski1, Maruša Debeljak2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23522890      PMCID： PMC3934229          DOI： 10.2450/2013.0229-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

Review 1.  Mild hemophilia A.

Authors:  M Franchini; E J Favaloro; G Lippi
Journal:  J Thromb Haemost       Date:  2009-12-07       Impact factor: 5.824

2.  Risk of inhibitor development in mild haemophilia A increases with age.

Authors:  E P Mauser-Bunschoten; I E M Den Uijl; R E G Schutgens; G Roosendaal; K Fischer
Journal:  Haemophilia       Date:  2011-08-19       Impact factor: 4.287

3.  Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.

Authors:  S Dunkley; G Kershaw; G Young; P Warburton; R Lindeman; S Matthews; F Rennisson
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287

Review 4.  Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.

Authors:  M Franchini; C Mengoli; G Lippi; G Targher; M Montagnana; G L Salvagno; M Zaffanello; M Cruciani
Journal:  Haemophilia       Date:  2008-07-28       Impact factor: 4.287

5.  Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

Authors:  C L Eckhardt; L A Menke; C H van Ommen; J H van der Lee; R B Geskus; P W Kamphuisen; M Peters; K Fijnvandraat
Journal:  J Thromb Haemost       Date:  2009-06       Impact factor: 5.824
  5 in total
  3 in total

1.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

2.  Low-dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  Tomaž Prelog; Majda Benedik Dolničar; Lidija Kitanovski
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

3.  Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.

Authors:  F Iioka; D Shimomura; F Nakamura; H Ohno; K Yada; K Nogami; M Shima
Journal:  Haemophilia       Date:  2014-11       Impact factor: 4.287
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.